Effects of nicotinamide riboside on metabolic health in obese humans

Completed

Conditions: Obesity
overweight
10018424

Registration Number: NL-OMON47018

Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 15

Inclusion Criteria

Caucasian
Males and postmenopausal females
Aged 45-65 years at start of the study
Body mass index (BMI) 27 * 35 kg/m2
Stable dietary habits (no weight loss or gain >5kg in the past 3 months)
Sedentary lifestyle (not more than 2 hours of intensive exercise per week)

Exclusion Criteria

Type 2 diabetes
Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)
Contra-indication for MRI
Participation in earlier research or medical examination that included PET/CT scanning
Alcohol consumption of >2 servings per day
Smoking in the past 6 months

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Hepatic and whole body insulin sensitivity.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Muscle mitochondrial function.<br /><br>Ectopic lipid accumulation (intrahepatic and intramuscular).<br /><br>Brown adipose tissue activity.<br /><br>Cardiovascular risk parameters: cardiac energy status, 24h average systolic and<br /><br>diastolic blood pressure, plasma cholesterol levels (cholesterol, HDL, LDL,<br /><br>lathosterol), plasma vasodilatation markers (VCAM1, ICAM1, E-selectin, nitrite)<br /><br>and plasma markers of low grade inflammation (TNF*, interleukins).<br /><br>Whole-body energy expenditure.<br /><br>Body composition (fat mass and fat free mass).<br /><br>Acetylcarnitine levels.</p><br>